JP2016516026A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516026A5
JP2016516026A5 JP2015562529A JP2015562529A JP2016516026A5 JP 2016516026 A5 JP2016516026 A5 JP 2016516026A5 JP 2015562529 A JP2015562529 A JP 2015562529A JP 2015562529 A JP2015562529 A JP 2015562529A JP 2016516026 A5 JP2016516026 A5 JP 2016516026A5
Authority
JP
Japan
Prior art keywords
alkyl
ethoxy
acetamide
oxo
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015562529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516026A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/059817 external-priority patent/WO2014141187A1/en
Publication of JP2016516026A publication Critical patent/JP2016516026A/ja
Publication of JP2016516026A5 publication Critical patent/JP2016516026A5/ja
Pending legal-status Critical Current

Links

JP2015562529A 2013-03-15 2014-03-14 Rearrangedduringtransfection(ret)キナーゼ阻害剤としてのピリジン誘導体 Pending JP2016516026A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/072683 2013-03-15
CN2013072683 2013-03-15
CN2013090059 2013-12-20
CNPCT/CN2013/090059 2013-12-20
CNPCT/CN2014/072449 2014-02-24
CN2014072449 2014-02-24
PCT/IB2014/059817 WO2014141187A1 (en) 2013-03-15 2014-03-14 Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2016516026A JP2016516026A (ja) 2016-06-02
JP2016516026A5 true JP2016516026A5 (enExample) 2017-04-13

Family

ID=50390154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562529A Pending JP2016516026A (ja) 2013-03-15 2014-03-14 Rearrangedduringtransfection(ret)キナーゼ阻害剤としてのピリジン誘導体

Country Status (33)

Country Link
US (2) US9382238B2 (enExample)
EP (1) EP2970191B1 (enExample)
JP (1) JP2016516026A (enExample)
CN (1) CN105051027A (enExample)
AU (1) AU2014229233B2 (enExample)
BR (1) BR112015023618A2 (enExample)
CA (1) CA2905627A1 (enExample)
CL (1) CL2015002514A1 (enExample)
CR (1) CR20150490A (enExample)
CY (1) CY1118730T1 (enExample)
DK (1) DK2970191T3 (enExample)
DO (1) DOP2015000244A (enExample)
EA (1) EA029296B1 (enExample)
ES (1) ES2616655T3 (enExample)
HR (1) HRP20170363T1 (enExample)
HU (1) HUE033423T2 (enExample)
IL (1) IL241161A0 (enExample)
LT (1) LT2970191T (enExample)
ME (1) ME02664B (enExample)
MX (1) MX2015012286A (enExample)
NZ (1) NZ628388A (enExample)
PE (1) PE20151538A1 (enExample)
PH (1) PH12015502044A1 (enExample)
PL (1) PL2970191T3 (enExample)
PT (1) PT2970191T (enExample)
RS (1) RS55710B1 (enExample)
SG (1) SG11201506695UA (enExample)
SI (1) SI2970191T1 (enExample)
SM (1) SMT201700152T1 (enExample)
TW (1) TW201524958A (enExample)
UA (1) UA115264C2 (enExample)
UY (1) UY35465A (enExample)
WO (1) WO2014141187A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
AU2015313894A1 (en) * 2014-09-08 2017-03-23 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
BR112017004897A2 (pt) * 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)
EP3517526B1 (en) 2014-09-10 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Pyridinones as rearranged during transfection (ret) inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RS65069B1 (sr) * 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
US10160747B2 (en) 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
EP3454886A1 (en) 2016-05-13 2019-03-20 Instituto de Medicina Molecular Methods of treating diseases associated with ilc3 cells
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20210290620A1 (en) 2017-05-15 2021-09-23 Blueprint Medicines Corporation Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
US10093648B1 (en) * 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
CN109096264B (zh) * 2018-08-28 2019-08-23 山东理工职业学院 Ret抑制剂及其制备方法、组合物和用途
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
JP7461605B2 (ja) * 2020-02-20 2024-04-04 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 キノリン系化合物
TWI777509B (zh) * 2020-04-27 2022-09-11 美商美國禮來大藥廠 用於抑制ret激酶之化合物
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
TWI786742B (zh) * 2020-07-23 2022-12-11 大陸商深圳晶泰科技有限公司 吡啶酮類化合物及其製備方法和應用
IL301817A (en) 2020-10-13 2023-06-01 Univ Johns Hopkins Modified 4-([4,2,1]triazolo[5,1-a]pyridin-6-yl)thiophene-2-carboxamide histories and their use
KR20230104146A (ko) * 2020-11-06 2023-07-07 일라이 릴리 앤드 캄파니 Ret 키나제 억제제로서의 피라졸 유도체
EP4347645A1 (en) 2021-06-03 2024-04-10 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud Foundation Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
CN115626880B (zh) * 2022-11-15 2023-11-14 常州大学 3-硝基-5-氰基三氟甲苯的合成方法
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法
EP4650002A1 (en) * 2024-05-15 2025-11-19 Ludwig-Maximilians-Universität Aniline-based modulators of the nuclear receptor tlx (nr2e1)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02001498A (es) 1999-08-12 2003-07-21 Pharmacia & Italia S P A Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
CN101558068A (zh) * 2006-10-16 2009-10-14 诺瓦提斯公司 用作蛋白激酶抑制剂的苯乙酰胺类
PL2848610T3 (pl) * 2006-11-15 2018-01-31 Ym Biosciences Australia Pty Inhibitory aktywności kinazy
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
AR095308A1 (es) 2013-03-15 2015-10-07 Glaxosmithkline Ip Dev Ltd Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento

Similar Documents

Publication Publication Date Title
ME02664B (me) Derivati premeštanja piridina u toku transfekcije inhibitora (ret) kinaze
JP2016528201A5 (enExample)
JP2017538750A5 (enExample)
JP2013510859A5 (enExample)
JP2018519323A5 (enExample)
JP2007519694A5 (enExample)
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
JP2016519685A5 (enExample)
RU2016141646A (ru) Ингибиторы trka киназы, основанные на них композиции и способы
JP2007519754A5 (enExample)
JP2014526500A5 (enExample)
JP2016536364A5 (enExample)
RU2017125520A (ru) Соединения, ингибирующие parg
HRP20130969T1 (hr) Spojevi spiropiperidona kao antagonisti receptora orl-1
HRP20170112T1 (hr) Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze
RU2013112122A (ru) Новые замещенные хинолиновые соединения как ингибиторы s-нитрозоглутатион-редуктазы
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
JP2017512786A5 (enExample)
RU2016133626A (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
HRP20130967T1 (hr) Spojevi spiropiperidona kao antagonisti receptora orl-1
RU2017116197A (ru) 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера
PE20191792A1 (es) Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos
HRP20200606T1 (hr) Derivati fenila kao agonisti kanabinoidnog receptora 2
JP2013525262A5 (enExample)
RU2013130879A (ru) Производные оксазолилметилового эфира в качестве агонистов рецептора alx